ProCE Banner Activity

Are We Treating HBV Early Enough?

Video

Join expert faculty as they answer important questions about how to expand HBV treatment candidacy for early treatment engagement, including adverse event considerations, cost-effectiveness, and clinical outcomes such as the potential impact on liver disease progression and HCC rates.

Released: March 07, 2024

Expiration: March 06, 2025

Share

Faculty

Jacki Chen

Jacki Chen, PhD

Patient Advocate

Tatyana Kushner

Tatyana Kushner, MD, MSCE

Associate Professor
Division of Liver Diseases
Icahn School of Medicine at Mount Sinai
New York, New York

Paul Y. Kwo

Paul Y. Kwo, MD

Professor of Medicine
Director of Hepatology
Stanford University School of Medicine
Palo Alto, California

Mark S. Sulkowski

Mark S. Sulkowski, MD, FIDSA, FAASLD

Professor of Medicine
Director, Division of Infectious Diseases, Johns Hopkins Bayview Medical Center
Johns Hopkins University School of Medicine
Baltimore, Maryland

Provided by

Provided by Clinical Care Options, LLC, in partnership with Hepatitis B Foundation.

ProCE Banner

Supporters

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.

Partners

Hepatitis B Foundation

ProCE Banner

Disclosure

Primary Author

Jacki Chen, PhD

Patient Advocate

Jacki Chen, PhD: consultant/advisor/speaker: GlaxoSmithKline.

Tatyana Kushner, MD, MSCE

Associate Professor
Division of Liver Diseases
Icahn School of Medicine at Mount Sinai
New York, New York

Tatyana Kushner, MD, MSCE: consultant/advisor/speaker: AbbVie, Eiger, Gilead, GlaxoSmithKline; researcher: Gilead.

Paul Y. Kwo, MD

Professor of Medicine
Director of Hepatology
Stanford University School of Medicine
Palo Alto, California

Paul Y. Kwo, MD: consultant/advisor/speaker: Aligos, Drug Farm, Eiger, Gilead, Inventiva; researcher: Altimmune, Bristol Myers Squibb, Eiger, Gilead, Janssen, Madrigal, Novo Nordisk, Salix, Ultragenyx.

Mark S. Sulkowski, MD, FIDSA, FAASLD

Professor of Medicine
Director, Division of Infectious Diseases, Johns Hopkins Bayview Medical Center
Johns Hopkins University School of Medicine
Baltimore, Maryland

Mark S. Sulkowski, MD, FIDSA, FAASLD: consultant/advisor/speaker: AbbVie, Aligos, Galapagos, Gilead, GlaxoSmithKline, Vir, Virion; researcher: Janssen, Virion; data and safety monitoring board: Immunocore.